EACH Coalition Submits Letter to CO PDAB on Affordability Review Rule Urging for More Patient Engagement
The EACH Coalition submitted comments ahead of the Stakeholder Meeting held on September 24th urging for increased patient engagement and […]
EACH Coalition Submits Letter to WA PDAB on Drug Review Process
As the Washington PDAB reviews its drug review process, the EACH Coalition submitted comments to the board outlining concerns with
EACH Coalition Submits Letter to MD PDAB on Draft UPL Plan
In response to the Maryland PDAB’s request for comments on their draft plan on Upper Payment Limits, the EACH Coalition
EACH Coalition Submits Letter to OR PDAB on Drug Review Process
As the Oregon PDAB reviews its drug review process, the EACH Coalition submitted comments to the board outlining concerns with
EACH Issues Statement on CMS Prices for First 10 Drugs Subject to Medicare Negotiation
“The EACH Coalition is dedicated to lowering drug costs for patients; however, we are concerned that price limits have little
EACH Coalition Submits Letter to MD PDAB on Drug Reviews and UPLs
In response to the Maryland PDAB’s request for comments on their selection of six drugs for cost review, the EACH
EACH Coalition Submits Testimony to WA PDAB on Therapeutic Alternatives
In response to the Washington PDAB’s request for input on therapeutic alternatives, the EACH Coalition submitted a testimony urging the
EACH Coalition Submits Letter to Colorado PDAB on Cosentyx and Stelara Unaffordability Decision
Following the decisions by the Colorado PDAB designating Cosentyx and Stelara as unaffordable to patients in Colorado, the EACH Coalition